DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6+ months with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Patients may be appropriate for DUPIXENT if they¹:

• Have tried a variety of topical Rx therapies and are still uncontrolled
• Suffer from inadequate control of pruritus
• Have ≥10% of their body covered with lesions and/or may involve problem areas such as the face, hands, and feet
• Have moderate-to-severe erythema and moderate-to-severe papulation/infiltration (Investigator's Global Assessment [IGA] score of 3=moderate or 4=severe)